Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,354.00
Bid: 12,352.00
Ask: 12,354.00
Change: -44.00 (-0.35%)
Spread: 2.00 (0.016%)
Open: 12,432.00
High: 12,482.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Sterling climbs above USD1.15, euro above parity

Wed, 26th Oct 2022 08:49

(Alliance News) - London's FTSE 100 index moved lower at the open on Wednesday, as the pound continued to climb higher on the potential for the stability that a Rishi Sunak premiership could bring to Westminster.

"After Liz Truss's terrible race for growth through unfunded tax cuts decimated the pound and sent government bond rates skyrocketing in the last month, the selection of Sunak has been hailed by financial markets as promising political stability," AvaTrade Chief Market Analyst Naeem Aslam said.

He added: "When compared to the dollar, the pound is almost 10% stronger than it was on September 26, when it set a record low, and the rates on gilts have returned to more normal levels after reaching excessive levels that caused pension funds to get agitated."

Sterling was quoted at USD1.1540 early Wednesday, sharply higher from USD1.1464 at the London equities close on Tuesday. The pound had not hit USD1.15 since mid-September.

Susannah Streeter, senior investment and markets analyst at Hargreaves Lansdown, commented: "Jeremy Hunt, the continuity candidate at the Treasury, is desperate for some dough to rise but recognises the risks of upsetting the bond market judges by not crossing out enough on his shopping list. Spending cuts are expected to be high on his page of ingredients for a more stable financial environment but that won’t help the head chef, Prime Minister Rishi Sunak, in the popularity stakes."

The FTSE 100 index was down 15.08 points, or 0.2%, at 6,998.40. The mid-cap FTSE 250 was down 53.44 points, or 0.3%, at 17,778.19, though the AIM All-Share was down just 0.11 of a point at 799.33.

The Cboe UK 100 was down 0.2% at 699.57, the Cboe UK 250 down 0.1% at 15,202.98, and the Cboe Small Companies flat at 12,269.58

In European equities on Tuesday, the CAC 40 in Paris was marginally higher, while the DAX 40 in Frankfurt was 0.2% lower.

In London, Scottish Mortgage Investment Trust was down 1.9% in early dealings as its tech stock-heavy investment portfolio was suffering from the disappointing results overnight from Alphabet and Microsoft.

Big technology shares Alphabet and Microsoft both lost more than 6% after releasing quarterly figures - Alphabet A shares lost 6.6% in after-hours trade in New York, while Microsoft lost 6.7%.

Alphabet reported a sharp fall in quarterly income on higher costs and foreign exchange headwinds but recorded a rise in revenue.

The California-based Google owner reported a 27% fall in net income to USD13.91 billion in the third quarter of 2022 compared to USD18.94 billion a year before.

More positively, revenue rose by 6.1% to USD69.09 billion in the period from USD65.12 billion. The company attributed the revenue growth to healthy fundamental growth in Search and momentum in the Cloud business.

Microsoft reported a rise in first-quarter earnings, with Chair & Chief Executive Satya Nadella arguing that digital technology was the "ultimate tailwind" in a world facing increasing challenges.

In the three months that ended September 30, revenue totalled USD50.12 billion, up 11% from USD45.32 billion the previous year. Revenue in the Intelligent Cloud segment increased by 20% against the previous year, while revenue in Productivity & Business Processes grew by 9.0%.

Microsoft, however, saw a fall in net income. The figure dropped 14% to USD17.56 billion from USD20.51 billion a year prior.

In the US, the week's strong rally continued, with stocks ending sharply higher on Tuesday, with the Dow Jones Industrial Average up 1.1%, the S&P 500 up 1.6%, and the Nasdaq Composite up 2.3%.

Back in London, WPP was at the bottom of the FTSE 100, giving back 3.5%.

Its third-quarter revenue rose 10% to GBP3.57 billion, with like-for-like revenue up 2.7%. The advertising and marketing firm noted its revenue less pass-through costs increased 13% to GBP2.99 billion.

Chief Executive Mark Read said the firm "continues to show strong momentum". He added: "Our growth over the year has been strong with full year like-for-like revenue less pass-through costs now upgraded to 6.5% to 7.0%."

Reckitt Benckiser was 3.0% lower.

The consumer healthcare firm's revenue increased by double-digit percentages in the third quarter, with its Hygiene, Health and Nutrition all seeing strong growth.

Total revenue was up 14% to GBP3.74 billion, with like-for-like revenue up 7.4%.

"Reckitt delivered another quarter of broad-based growth amidst challenging market conditions, as we continue to innovate and improve on our in-market execution," Chief Executive Nicandro Durante said.

"My priority is firmly focussed on continuing to execute on our strategic path, to deliver sustainable mid-single digit growth, and mid-20s adjusted operating margins by the mid-2020s." Reckitt narrowed its like-for-like net revenue growth target for 2022 upward to 6% to 8% from 5% to 8% previously.

At the other end of the blue chips, AstraZeneca was up 2.6% - crowning the FTSE 100.

The healthcare giant was on the rise after its CAPItello-291 Phase III trial showed its capivasertib, in combination with Faslodex, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo in patients with advanced or metastatic breast cancer.

The trial met both primary endpoints.

Susan Galbraith, executive vice president of Oncology R&D at Astra, said the data was "exciting" and shows capivasertib could become a "new first-in-class treatment option".

The euro traded at USD1.002 early Wednesday, moving back above parity for the first time since the start of October, and up from USD0.9963 late Tuesday. Against the yen, the dollar was quoted at JPY147.38, down from JPY147.77.

In Asia, the Shanghai Composite closed up 0.8% and the Hang Seng index in Hong Kong added 0.7%. The Japanese Nikkei 225 index closed up 0.7%.

The S&P/ASX 200 stock index in Sydney closed up 0.2%.

Gold was quoted at USD1,666.70 an ounce early Wednesday, higher than USD1,655.96 on Tuesday evening in London. Brent oil was trading at USD90.49 a barrel, down from USD91.91 late Tuesday.

In the economic calendar, there's a US goods trade balance print, before the Bank of Canada issues an interest rate decision at 1500 BST.

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.